BioCryst Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
109.38 M |
Public Float |
83.54 M |
BioCryst Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1 |
Market Cap |
$411.47 M |
Shares Outstanding |
110.31 M |
Public Float |
108.28 M |
Address |
4505 Emperor Boulevard Durham North Carolina 27703 United States |
Employees | - |
Website | http://www.biocryst.com |
Updated | 07/08/2019 |
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. |